1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > HIV-1 Infection Global Clinical Trials Review, H2, 2014

HIV-1 Infection Global Clinical Trials Review, H2, 2014

  • November 2014
  • -
  • Global Data
  • -
  • 164 pages

HIV-1 Infection Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “HIV-1 Infection Global Clinical Trials Review, H2, 2014" provides data on the HIV-1 Infection clinical trial scenario. This report provides elemental information and data relating to the clinical trials on HIV-1 Infection. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating HIV-1 Infection. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

HIV-1 Infection Global Clinical Trials Review, H2, 2014
Table of Contents

Introduction 6
HIV-1 Infection 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of HIV-1 Infection to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of HIV-1 Infection to Infectious Disease Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of HIV-1 Infection 25
Subjects Recruited Over a Period of Time 34
Clinical Trials by Sponsor Type 35
Prominent Sponsors 36
Top Companies Participating in HIV-1 Infection Therapeutics Clinical Trials 37
Prominent Drugs 38
Latest Clinical Trials News on HIV-1 Infection 39
Nov 11, 2014: AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting 2014 39
Nov 03, 2014: Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients 40
Oct 13, 2014: CytoDyn Announces 100% Success With PRO 140 in Four-Week Monotherapy Clinical Trial 41
Sep 24, 2014: Gilead's Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies 42
Clinical Trial Profiles 44
Clinical Trial Overview of Top Companies 44
GlaxoSmithKline plc 44
Clinical Trial Overview of GlaxoSmithKline plc 44
Gilead Sciences, Inc. 54
Clinical Trial Overview of Gilead Sciences, Inc. 54
Merck and Co., Inc. 61
Clinical Trial Overview of Merck and Co., Inc. 61
C. H. Boehringer Sohn AG and Co. KG 66
Clinical Trial Overview of C. H. Boehringer Sohn AG and Co. KG 66
Pfizer Inc. 70
Clinical Trial Overview of Pfizer Inc. 70
F. Hoffmann-La Roche Ltd. 74
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 74
Johnson and Johnson 78
Clinical Trial Overview of Johnson and Johnson 78
Bristol-Myers Squibb Company 82
Clinical Trial Overview of Bristol-Myers Squibb Company 82
Abbott Laboratories 85
Clinical Trial Overview of Abbott Laboratories 85
Janssen RandD Ireland 87
Clinical Trial Overview of Janssen RandD Ireland 87
Clinical Trial Overview of Top Institutes / Government 89
The National Institute of Allergy and Infectious Diseases 89
Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 89
French National Agency for Research on AIDS and Viral Hepatitis 100
Clinical Trial Overview of French National Agency for Research on AIDS and Viral Hepatitis 100
AIDS Clinical Trials Group 103
Clinical Trial Overview of AIDS Clinical Trials Group 103
University of California, San Francisco 105
Clinical Trial Overview of University of California, San Francisco 105
Hospital Clinic de Barcelona 106
Clinical Trial Overview of Hospital Clinic de Barcelona 106
University of Washington 107
Clinical Trial Overview of University of Washington 107
Imperial College London 108
Clinical Trial Overview of Imperial College London 108
University of North Carolina 109
Clinical Trial Overview of University of North Carolina 109
International Partnership For Microbicides 110
Clinical Trial Overview of International Partnership For Microbicides 110
Medical Research Council 111
Clinical Trial Overview of Medical Research Council 111
Five Key Clinical Profiles 112
Appendix 162
Abbreviations 162
Definitions 162
Research Methodology 163
Secondary Research 163
About GlobalData 164
Contact Us 164
Disclaimer 164
Source 164

List of Tables

HIV-1 Infection Therapeutics, Global, Clinical Trials by Region, 2014* 7
HIV-1 Infection Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
HIV-1 Infection Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
HIV-1 Infection Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
HIV-1 Infection Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
HIV-1 Infection Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
HIV-1 Infection Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
HIV-1 Infection Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of HIV-1 Infection to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
HIV-1 Infection Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
HIV-1 Infection Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of HIV-1 Infection to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
HIV-1 Infection Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
HIV-1 Infection Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
HIV-1 Infection Therapeutics, Global, Clinical Trials by Phase, 2014* 21
HIV-1 Infection Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
HIV-1 Infection Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
HIV-1 Infection Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
HIV-1 Infection Therapeutics, Global, Suspended Clinical Trials, 2014* 25
HIV-1 Infection Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
HIV-1 Infection Therapeutics, Global, Terminated Clinical Trials, 2014* 28
HIV-1 Infection Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 34
HIV-1 Infection Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 35
HIV-1 Infection Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 36
HIV-1 Infection Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 37
HIV-1 Infection Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 38
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 44
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2014* 54
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 61
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG and Co. KG, 2014* 66
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 70
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 74
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2014* 78
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 82
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by Abbott Laboratories, 2014* 85
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by Janssen RandD Ireland, 2014* 87
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014* 89
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by French National Agency for Research on AIDS and Viral Hepatitis, 2014* 100
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by AIDS Clinical Trials Group, 2014* 103
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 105
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by Hospital Clinic de Barcelona, 2014* 106
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014* 107
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by Imperial College London, 2014* 108
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by University of North Carolina, 2014* 109
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by International Partnership For Microbicides, 2014* 110
HIV-1 Infection Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical Research Council, 2014* 111

List of Figures

HIV-1 Infection Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
HIV-1 Infection Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
HIV-1 Infection Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
HIV-1 Infection Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
HIV-1 Infection Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
HIV-1 Infection Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
HIV-1 Infection Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
HIV-1 Infection Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of HIV-1 Infection to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
HIV-1 Infection Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
HIV-1 Infection Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of HIV-1 Infection to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
HIV-1 Infection Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
HIV-1 Infection Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
HIV-1 Infection Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
HIV-1 Infection Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
HIV-1 Infection Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
HIV-1 Infection Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
HIV-1 Infection Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 34
HIV-1 Infection Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 35
HIV-1 Infection Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 36
HIV-1 Infection Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 37
HIV-1 Infection Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 38
GlobalData Methodology 163

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.